Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jan 6, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.8K

基于基因表达特征的测试来预测黑色素瘤哨兵节点状态:MERLIN_001研究

Tina J Hieken1, Michael E Egger2, Christina V Angeles3

  • 1Departments of Surgery and Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota.

JAMA surgery
|October 22, 2025
PubMed
概括

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Circulating and brain-resident memory CD8+ T cells seed distinct bystander T <sub>RM</sub> -like populations in glioblastoma.

bioRxiv : the preprint server for biology·2026
Same author

Neoadjuvant PD-1 Blockade in Surgically Resectable Desmoplastic Melanoma: Cohort A of the Phase 2 SWOG S1512 Trial.

Annals of surgical oncology·2026
Same author

On the survival benefit from sentinel node biopsy for melanoma.

The Lancet. Oncology·2026
Same author

Is Immediate Lymphatic Reconstruction Cost-Effective for Breast Cancer Lymphedema?

Plastic and reconstructive surgery·2026
Same author

The promise of immunotherapy in the treatment of sarcoma: A state-of-the-art review of practice changing research and future directions.

Human vaccines & immunotherapeutics·2026
Same author

Perspective Editorial: Assessment of Survival Benefit from Sentinel Node Biopsy for Melanoma: A Systematic Review and Meta-analysis.

Annals of surgical oncology·2026
Same journal

In Support of Collaborative Pediatric Device Innovation.

JAMA surgery·2026
Same journal

Benefits of Surgical Stabilization of Rib Fractures and Delayed Operation.

JAMA surgery·2026
Same journal

Errors in Methods and Supplement 1.

JAMA surgery·2026
Same journal

Lumpectomy Margins and Local Recurrence in DCIS: Results From the NRG Oncology/NSABP B-35 Randomized Clinical Trial.

JAMA surgery·2026
Same journal

A Closer Look at Costs of California Hospital Operating Rooms.

JAMA surgery·2026
Same journal

In Support of Collaborative Pediatric Device Innovation-Reply.

JAMA surgery·2026
查看所有相关文章
此摘要是机器生成的。

一项新的联合临床病理因素和基因表达特征 (CP-GEP) 测试准确地识别了患有黑色素瘤的患者,这些患者患有哨兵淋巴结转移 (SLNM) 的风险很低. 该测试有助于决策的哨兵淋巴结活检 (SLNB),可能节省患者不必要的程序.

科学领域:

  • 在瘤学瘤学.
  • 皮肤病学 皮肤病学
  • 基因组学就是基因组学.
  • 手术病理学手术病理学

背景情况:

  • 当代指导方针建议在患有>10% SLN 转移风险的黑色素瘤患者中进行哨戒淋巴结活检 (SLNB).
  • 准确识别低风险患者可以改进SLNB选择,避免不必要的程序.
  • 基于基因表达特征 (GEP) 的测试为改善风险分层提供了潜力.

研究的目的:

  • 为了评估结合临床病理因素和GEP (CP-GEP) 测试的预测能力.
  • 为了确定可以安全地放弃SLNB的原发性皮肤黑色素瘤患者.
  • 为了评估CP-GEP的预后价值,在负SLNB (不在这里报告) 后的结果.

主要方法:

  • 一项多中心,前性,盲目预后研究,涉及1761名T1-T3皮肤黑色素瘤患者.
  • 在初级黑色素瘤组织上进行了CP-GEP测试,以评估SLN转移风险.
  • 根据标准临床标准,患者被认为是SLNB的候选人.

主要成果:

  • 在CP-GEP测试中,37.0%的患者被确定为低风险患者,SLN转移的负预测值 (NPV) 为92.9%.
  • 高风险病例的SLN阳性率 (23.8%) 与低风险病例 (7.1%) 相比显著更高.

更多相关视频

Experimental Metastasis Assay
08:28

Experimental Metastasis Assay

Published on: August 24, 2010

20.8K
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.3K

相关实验视频

Last Updated: Jan 6, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

2.8K
Experimental Metastasis Assay
08:28

Experimental Metastasis Assay

Published on: August 24, 2010

20.8K
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.3K
  • 低风险CP-GEP结果的比例随着瘤阶段的增加而下降 (T1: 68.2%,T2: 32.9%,T3: 2.8%).

    • 结论:

    • 在CP-GEP测试可靠地识别黑色素瘤患者的低风险 (<10%) 的哨兵淋巴结转移.
    • 在高风险与低风险的CP-GEP病例中,SLN转移率大约是高风险的三倍.
    • CP-GEP可以加强患者和外科医生之间关于SLNB的共享决策.